Why is UroGen Pharma Ltd. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 0.29% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -25.07
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 125.76%, its profits have fallen by -21%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is UroGen Pharma Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
UroGen Pharma Ltd.
138.84%
2.36
69.12%
S&P 500
25.22%
1.92
13.25%
Quality key factors
Factor
Value
Sales Growth (5y)
56.22%
EBIT Growth (5y)
0.29%
EBIT to Interest (avg)
-25.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.58
Sales to Capital Employed (avg)
2.91
Tax Ratio
2.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-7.92
EV to EBIT
-6.71
EV to EBITDA
-6.84
EV to Capital Employed
-8.11
EV to Sales
7.63
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
Technical Movement
22What is working for the Company
NET SALES(Q)
Highest at USD 50.96 MM
OPERATING PROFIT MARGIN(Q)
Highest at -38.48 %
RAW MATERIAL COST(Y)
Fallen by -3.86% (YoY
NET PROFIT(Q)
Highest at USD -23.57 MM
EPS(Q)
Highest at USD -0.47
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -175.59 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 1 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.74 times
Here's what is working for UroGen Pharma Ltd.
Net Sales
At USD 50.96 MM has Grown at 151.6%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 50.96 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -38.48 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Highest at USD -23.57 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.47
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -3.86% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for UroGen Pharma Ltd.
Operating Cash Flow
Lowest at USD -175.59 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Inventory Turnover Ratio
Lowest at 1 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.74 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio






